GeneDx (NASDAQ:WGS) PT Raised to $15.00 at BTIG Research

GeneDx (NASDAQ:WGS - Get Free Report) had its target price upped by equities research analysts at BTIG Research from $11.00 to $15.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's price objective points to a potential upside of 44.37% from the stock's current price.

Separately, The Goldman Sachs Group upped their target price on shares of GeneDx to $11.00 and gave the stock a "neutral" rating in a research report on Monday, April 15th.

GeneDx Stock Performance

WGS traded up $0.75 during trading on Monday, hitting $10.39. The stock had a trading volume of 131,713 shares, compared to its average volume of 243,887. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.95 and a current ratio of 3.10. The firm has a market capitalization of $270.66 million, a P/E ratio of -1.40 and a beta of 2.75. GeneDx has a twelve month low of $1.16 and a twelve month high of $12.24. The company's 50-day moving average price is $8.58 and its 200 day moving average price is $4.75.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, February 20th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. The company had revenue of $57.42 million during the quarter, compared to the consensus estimate of $57.00 million. On average, equities research analysts forecast that GeneDx will post -2.02 EPS for the current fiscal year.

Insider Activity at GeneDx

In other news, Director Casdin Capital, Llc acquired 40,000 shares of the business's stock in a transaction dated Monday, March 4th. The stock was acquired at an average price of $8.74 per share, with a total value of $349,600.00. Following the completion of the transaction, the director now directly owns 2,702,609 shares in the company, valued at approximately $23,620,802.66. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Kevin Feeley sold 3,253 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $10.59, for a total value of $34,449.27. Following the completion of the sale, the chief financial officer now owns 28,927 shares of the company's stock, valued at $306,336.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Casdin Capital, Llc purchased 40,000 shares of the firm's stock in a transaction that occurred on Monday, March 4th. The shares were acquired at an average cost of $8.74 per share, with a total value of $349,600.00. Following the completion of the transaction, the director now owns 2,702,609 shares in the company, valued at approximately $23,620,802.66. The disclosure for this purchase can be found here. Insiders have sold a total of 13,820 shares of company stock valued at $146,354 over the last quarter. Insiders own 28.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Decheng Capital LLC purchased a new position in GeneDx in the 4th quarter valued at about $285,000. Thompson Davis & CO. Inc. lifted its stake in shares of GeneDx by 99.4% in the fourth quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company's stock worth $55,000 after acquiring an additional 9,944 shares in the last quarter. Oracle Investment Management Inc. boosted its stake in shares of GeneDx by 14.9% during the 3rd quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company's stock valued at $3,620,000 after buying an additional 128,731 shares during the last quarter. HighTower Advisors LLC grew its position in shares of GeneDx by 14.1% in the 3rd quarter. HighTower Advisors LLC now owns 237,948 shares of the company's stock worth $865,000 after acquiring an additional 29,361 shares in the last quarter. Finally, Pathstone Family Office LLC lifted its stake in GeneDx by 262.2% during the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company's stock worth $198,000 after purchasing an additional 39,327 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.